<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718950</url>
  </required_header>
  <id_info>
    <org_study_id>i-LAB</org_study_id>
    <secondary_id>U1111-1178-4180</secondary_id>
    <nct_id>NCT02718950</nct_id>
  </id_info>
  <brief_title>Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans</brief_title>
  <acronym>i-LAB</acronym>
  <official_title>Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to access liraglutide influence brown adipose tissue recruitment&#xD;
      and its thermogenic effect through hypothalamic activation in obese individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans</measure>
    <time_frame>2 weeks</time_frame>
    <description>Activation of BAT, as considered Standard Uptake Value (SUV) threshold of 2.0 on 18-FDG-PET CT, prior to liraglutide use and after 2 weeks on liraglutide 3.0 mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of liraglutide administration on hypothalamic activation in humans</measure>
    <time_frame>2 weeks</time_frame>
    <description>Evaluate the effect of liraglutide administration on hypothalamic tract activation as assessed by magnetic resonance image in humans prior and after 2 weeks on liraglutide 3.0 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of liraglutide administration on non-shivering thermogenesis in humans</measure>
    <time_frame>2 weeks</time_frame>
    <description>Evaluate the effect of liraglutide administration on non-shivering thermogenesis by infrared thermography and indirect calorimetry in humans prior and after 2 weeks on liraglutide 3.0 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of liraglutide administration on body weight in humans</measure>
    <time_frame>2 weeks</time_frame>
    <description>Evaluate the effect of liraglutide administration on total body weight (kg) in humans prior and after 2 weeks on liraglutide 3.0 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of liraglutide administration on metabolic basal rate in humans</measure>
    <time_frame>2 weeks</time_frame>
    <description>Evaluate the effect of liraglutide administration on basal kilocalories/day in humans prior and after 2 weeks on liraglutide 3.0 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of liraglutide administration on body composition in humans</measure>
    <time_frame>2 weeks</time_frame>
    <description>Evaluate the effect of liraglutide administration on lean mass and fat percentage as assessed by dual x-ray absorptiometry (DXA) in humans prior and after 2 weeks on liraglutide 3.0 mg</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Liraglutide 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use liraglutide 3.0 mg for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide 3.0 mg</intervention_name>
    <description>Subjects will use liraglutide 3.0 mg for 2 weeks</description>
    <arm_group_label>Liraglutide 3.0 mg</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index over 30 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to liraglutide or any of its vehicle components;&#xD;
&#xD;
          -  History of diabetes or pre-diabetes - either by fasting glycemia, oGTT or HbA1c;&#xD;
&#xD;
          -  Previous treatment within the last 3 months with glucagon like peptide-1 agonists,&#xD;
             iDPP4 or any medication that is associated with BAT activation, including propranolol&#xD;
             and benzodiazepines;&#xD;
&#xD;
          -  Liver diseases, except non-alcoholic steatohepatitis (NASH);&#xD;
&#xD;
          -  Infection by HIV, hepatitis B or hepatitis C;&#xD;
&#xD;
          -  Addiction to cannabis, heroin, morphine, cocaine, benzodiazepines or amphetamine;&#xD;
&#xD;
          -  Obesity induced by other disorders such as Cushing syndrome, hypothyroidism,&#xD;
             lipodystrophy&#xD;
&#xD;
          -  Current or history of treatment with medications that may cause significant weight&#xD;
             gain within 3 months prior to screening, including systemic corticosteroids (except&#xD;
             for a short course of treatment, i.e. 7-10 days), tricyclic antidepressants, atypical&#xD;
             antipsychotic and mood stabilizers (e.g. imipramine, amitriptyline, mirtazapine,&#xD;
             paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic&#xD;
             acid and its derivatives, and lithium);&#xD;
&#xD;
          -  Current participation (or within the last 3 months) in an organized weight reduction&#xD;
             program&#xD;
&#xD;
          -  Currently or previous using within 3 months before screening of pramlintide,&#xD;
             sibutramine, orlistat, topiramate, or metformin (either by prescription or as part of&#xD;
             a clinical trial)&#xD;
&#xD;
          -  Participation in a clinical trial within the last 3 months prior to screening&#xD;
&#xD;
          -  Simultaneous participation in any other clinical trial of an investigational drug&#xD;
&#xD;
          -  Previous surgical treatment of obesity;&#xD;
&#xD;
          -  Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer),&#xD;
             which in the investigator's opinion could interfere with the results of the trial&#xD;
&#xD;
          -  Liver enzyme (ALT and AST) above 2.5 x of reference range&#xD;
&#xD;
          -  Pancreatic enzymes (amylase, lipase) above 3 x the reference range&#xD;
&#xD;
          -  Chronic kidney disease stages 3, 4, or 5&#xD;
&#xD;
          -  Relevant inflammatory or acute or chronic infectious disease; hyperthyroidism;&#xD;
             neurological, psychiatric, gastrointestinal, respiratory, renal, hepatic or cardiac&#xD;
             relevant disease, that could interfere with trial results per the judgment of&#xD;
             investigator&#xD;
&#xD;
          -  Any condition that at the discretion of investigator could interfere with treatment&#xD;
             adhesion on patient safety&#xD;
&#xD;
          -  Blood donation or transfusion within the last 3 months&#xD;
&#xD;
          -  Pregnancy or intention of pregnancy&#xD;
&#xD;
          -  History of Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2)&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  Less than 80% of liraglutide adherence&#xD;
&#xD;
          -  Calcitonin above the reference range at the screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Geloneze, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lício A Velloso, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José C Lima Júnior, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Campinas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Riobaldo M Cintra, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Campinas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Geloneze, MD, PhD</last_name>
    <phone>+55 19 35218589</phone>
    <email>bgeloneze@terra.com.br</email>
  </overall_contact>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Bruno Geloneze</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Brown Adipose Tissue</keyword>
  <keyword>Hypothalamic Activation</keyword>
  <keyword>Non-shivering Thermogenesis</keyword>
  <keyword>Basal Metabolic Rate</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Victoza</keyword>
  <keyword>Body Composition</keyword>
  <keyword>Body weight</keyword>
  <keyword>Adipose Tissue Biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

